Vaccine Info


In Affinivax’s MAPS vaccine against pneumococcus, proprietary pneumococcal protein antigens enable the potential for an additional immune response to protect against disease due to a broader range of ‘non-vaccine’ pneumococcal serotypes, beyond what is covered by today’s vaccines.

The MAPS complex also enables these protein antigens to elicit a T cell response to reduce nasopharyngeal colonization (nasal carriage of pneumococcal bacteria), the first and essential step in pneumococcal infection. 

ASP3772 is in a Phase 1 clinical trial.

April 2nd, 2019